Eton (ETON) Q1 2026 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Fri, May 15, 2026 astatine 12:21 PM CDT 29 min read

Image source: The Motley Fool.

Date

Thursday, May 14, 2026 astatine 4:30 p.m. ET

Call participants

• Chief Executive Officer — Sean Brynjelsen

• Chief Financial Officer — James Gruber

• Chief Commercial Officer — Ipek Erdogan-Trinkaus

• Executive Vice President of Accounting and Finance — Judy Matthews

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Sean Brynjelsen: Thank you, David. Good afternoon, everyone, and convey you for joining america today. The archetypal 4th was different large 4th for Eton. We achieved grounds merchandise income delivering 73% year-over-year merchandise gross growth. We launched 2 caller large products, DESMODA and HEMANGEOL. And we made large strides advancing our R&D programs with the accomplishment of respective improvement milestones. We volition sermon each of these items and much connected the telephone today. On the quarterly results, it was different large 4th for Eton with $24 cardinal successful merchandise sales, an summation of 73% year-over-year.

Our maturation continues to beryllium driven by contributions crossed the merchandise portfolio, including INCRELEX, ALKINDI, GALZIN and Carglumic Acid, highlighting the diversification and durability of our uncommon illness portfolio. This awesome gross maturation did not adjacent see the payment of the merchandise launches of DESMODA and HEMANGEOL since they launched successful mid-March and May, respectively. Based connected the outperformance successful the archetypal 4th and the trends we are seeing midway done the 2nd quarter, I'm pleased to study that we are raising our afloat twelvemonth gross guidance. We present expect gross to transcend $120 million, up from our erstwhile guidance of $110 million. Importantly, we delivered this notable archetypal 4th gross maturation successful a highly profitable manner.

We grew merchandise gross by 73%, but G&A spending accrued by lone 14% year-over-year connected a GAAP ground and 22% connected a non-GAAP basis. The bulk of the G&A summation was owed to accrued costs of FDA yearly programme fees present that we nary longer suffice for the orphan PDUFA exemption alternatively than the existent increases successful our discretionary spend. Adjusted EBITDA for the 4th was $5.7 cardinal oregon 24% of revenue. We proceed to expect to execute a greater than 30% adjusted EBITDA borderline for the afloat twelvemonth and judge we are connected way to scope our extremity of a 50% adjusted EBITDA borderline by 2028.

The results are a testament to the effectiveness and scalability of our unsocial uncommon illness exemplary and infrastructure. Our nimble proven infrastructure has allowed america to motorboat 2 caller products successful 2026 truthful acold without a important summation successful expenses and without impacting the execution of maturation successful our existing portfolio. We expect to spot akin trends successful the coming quarters arsenic we proceed to rapidly turn gross and bring to marketplace caller uncommon illness therapies. Turning to merchandise specifics. I volition commencement with our breathtaking caller motorboat of HEMANGEOL, which took spot conscionable a substance of days ago.